- Home
- GMAB vs AGR Comparison
GMAB vs AGR Comparison
Compare GMAB & AGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- AGR
- Stock Information
- Founded
- GMAB 1999
- AGR 1847
- Country
- GMAB Denmark
- AGR United States
- Employees
- GMAB N/A
- AGR N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- AGR Electric Utilities: Central
- Sector
- GMAB Health Care
- AGR Utilities
- Exchange
- GMAB Nasdaq
- AGR Nasdaq
- Market Cap
- GMAB 15.0B
- AGR 14.0B
- IPO Year
- GMAB N/A
- AGR N/A
- Fundamental
- Price
- GMAB $20.31
- AGR $35.73
- Analyst Decision
- GMAB Buy
- AGR Sell
- Analyst Count
- GMAB 8
- AGR 3
- Target Price
- GMAB $43.00
- AGR $34.50
- AVG Volume (30 Days)
- GMAB 1.2M
- AGR 852.8K
- Earning Date
- GMAB 02-12-2025
- AGR 02-19-2025
- Dividend Yield
- GMAB N/A
- AGR 4.89%
- EPS Growth
- GMAB 14.35
- AGR 111.64
- EPS
- GMAB 10.80
- AGR 2.90
- Revenue
- GMAB $2,967,926,227.00
- AGR $8,705,000,000.00
- Revenue This Year
- GMAB $30.31
- AGR $2.67
- Revenue Next Year
- GMAB $16.49
- AGR $3.35
- P/E Ratio
- GMAB $18.44
- AGR $12.42
- Revenue Growth
- GMAB 17.75
- AGR 6.35
- 52 Week Low
- GMAB $19.85
- AGR $29.71
- 52 Week High
- GMAB $32.88
- AGR $37.70
- Technical
- Relative Strength Index (RSI)
- GMAB 36.70
- AGR 49.87
- Support Level
- GMAB $19.99
- AGR $35.49
- Resistance Level
- GMAB $21.03
- AGR $35.75
- Average True Range (ATR)
- GMAB 0.38
- AGR 0.12
- MACD
- GMAB -0.07
- AGR 0.00
- Stochastic Oscillator
- GMAB 18.55
- AGR 80.64
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About AGR Avangrid Inc.
Avangrid operates two business units, Networks and Renewables. Networks operates eight regulated electric and natural gas utilities across New York, Maine, Connecticut, and Massachusetts, serving over 3 million customers. Renewables has historically focused on developing onshore wind projects but is looking to make developments in solar and offshore wind over the next five years. It operates nearly 8.6 gigawatts of renewable energy projects across the U.S. Spanish utility Iberdrola spun off Avangrid's predecessor, Iberdrola USA, in 2015. Iberdrola owns 81.6% of Avangrid and has proposed to acquire the remaining shares.